Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07138001) titled 'Phase 2 Clinical Trial of KH617' on Aug. 15.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Sichuan Honghe Biotechnology Co., Ltd.
Condition:
Recurrent Glioblastoma
Intervention:
Combination Product: KH617+TMZ
Drug: KH617
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: August 2025
Target Sample Size: 60
To know more, visit https://clinicaltrials.gov/ct2/show/NCT07138001
Published by HT Digital Content Services with permission from Health Daily ...